Oglufanide

Summary

Oglufanide (CHEMBL2111029) is a phase-3 clinical-stage small-molecule immunomodulator.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 333.34 Da · C16H19N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111029
Name	Oglufanide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	100094
ChEBI	CHEBI:73512
Molecular formula	C16H19N3O5
Molecular weight	333.34
InChIKey	LLEUXCDZPQOJMY-AAEUAGOBSA-N

SMILES: C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)N

IUPAC name: (4S)-4-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

ChEBI definition: A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage.

Pharmacological roles (ChEBI): immunomodulator, angiogenesis modulating agent, antineoplastic agent.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: NSC-334073, Oglufanida, Oglufanide, OGLUFANIDE

Parent form; salt/anhydrous children: CHEMBL2107123

Patent coverage: 206 distinct patent families (558 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).